Navigation Links
Sierra Oncology Announces Proposed Public Offering of Common Stock
Date:2/8/2017

VANCOUVER, Feb. 8, 2017 /PRNewswire/ - Sierra Oncology, Inc. (NASDAQ: SRRA), a clinical stage drug development company focused on advancing next generation DNA Damage Response therapeutics for the treatment of patients with cancer, today announced that it intends to offer and sell, subject to market conditions, shares of its common stock in an underwritten public offering. All of the shares to be sold in the offering will be offered by Sierra Oncology. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. In addition, Sierra Oncology intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering.

Jefferies LLC is acting as the sole book-running manager for the offering.

Sierra Oncology intends to use the net proceeds from the public offering to fund development of its product candidates, SRA737 and SRA141, as well as for general corporate purposes.

The securities described above are being offered by Sierra Oncology pursuant to a registration statement on Form S-3 (File No. 333-212793) that was declared effective by the Securities and Exchange Commission (SEC) on August 11, 2016. A preliminary prospectus supplement and an accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's web site at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone at 877-547-6340, or by email at prospectus_department@jefferies.com.

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

Cautionary Note on Forward-Looking Statements This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding Sierra Oncology's intention to conduct an offering and sale of securities, ability to complete the offering and expected use of proceeds. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties, including the risk factors described under the heading "Risk Factors" set forth in Sierra Oncology's filings with the Securities and Exchange Commission from time to time, including the Company's reports filed with the Securities and Exchange Commission. Sierra Oncology undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.


'/>"/>
SOURCE Sierra Oncology
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Sierra Wins the 2013 Laboratory Equipment Readers’ Choice Award
2. Prova Education Hires Oncology Expert Alana Brody to Further Expand its Oncology Education and Opportunities
3. MannKind, Ariad Pharma, Ziopharm Oncology, Galena Biopharma, and Novavax Under StockCalls Microscope
4. Predictive Biomarker Discovery for Oncology Small-Molecules and Biologics - a Webinar Hosted by Xtalks
5. Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting
6. Project Oncology CME Series Launches on ReachMD, Offering Learners a Wide Array of Certified Oncology Activities Across an Integrated Platform
7. ReachMD Adds ‘Oncology Power Hour’ to Weekly Line Up, Delivering Expert Opinions and Medical Interviews to On Air, Online, and Mobile Learners
8. AbbVie Presents Results from Phase I Study of Investigational Oncology Compound ABT-199 at American Society of Clinical Oncology Annual Meeting
9. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
10. Closed Drug Transfer Systems: Oncology Therapeutics Market Dynamics and Closed Drug Transfer Design Factors - Market Forecasts to 2017
11. Vermillions OVA1 Receives New Statement by Society of Gynecologic Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2018)... ... August 17, 2018 , ... VANCOUVER, British Columbia, Canada, ... is pleased to announce the release of the Russian translation of Best Practices: ... January 2018, is a practice-changing publication aimed at advancing the science of biobanking ...
(Date:8/14/2018)... ... August 14, 2018 , ... ... at the 11th Congress of the Chinese Association of Orthopaedic Surgeons (CAOS) held ... Fule Science & Technology Development , Beijing, and Invibio Biomaterial Solutions ...
(Date:8/9/2018)... ... 2018 , ... ActX introduces GenoACT(sm), a Genetic Clinical Decision ... talented scientific team that includes geneticists, PharmD’s, genetic counselors, and physicians aided by ... medical impact of a patient’s genetic variants , 2. Educational information for clinicians, ...
(Date:8/9/2018)... LITTLE ROCK, Ark. (PRWEB) , ... August 09, ... ... of practice management (PM), revenue cycle management (RCM), patient engagement and analytics software ... fiscal year 2018 was the highest in its twenty-year history. After back-to-back record ...
Breaking Biology Technology:
(Date:8/14/2018)... ... August 13, 2018 , ... Career fairs provide ... with multiple health systems at once. However, healthcare professionals often have hectic schedules ... efficient option for healthcare providers who wish to explore opportunities and learn about ...
(Date:8/14/2018)... ... August 13, 2018 , ... NRD, ... P-2021-5502 and P-2021-5602 Cleanroom Ionizing Gun. , The ionizing gun features ergonomic ... P-2021 ionizing cartridge, 0.5-micron filter and electropolished OSHA-compliant tip. This can be cleanroom ...
(Date:8/14/2018)... Fla. (PRWEB) , ... August 14, 2018 , ... ... activity and sleep monitoring solutions for the global scientific community, announced today the ... focus of this new division is to foster and support scientific collaborations with ...
Breaking Biology News(10 mins):